Black Diamond Therapeutics Inc
NASDAQ: BDTX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Black Diamond Therapeutics Inc (BDTX) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $0.00 | $-4.60M | — | — | — |
| 2018 | $0.00 | $-8.93M | — | — | — |
| 2019 | $0.00 | $-35.26M | — | — | — |
| 2020 | $0.00 | $-67.25M | — | — | — |
| 2021 | $0.00 | $-125.60M | — | — | — |
| 2022 | $0.00 | $-91.17M | — | — | — |
| 2023 | $0.00 | $-82.44M | — | — | — |
| 2024 | $0.00 | $-69.68M | — | — | — |
| 2025 | $70.00M | $22.37M | 99.54% | 28.39% | 31.95% |
Frequently asked questions
How profitable is BDTX?
In its most recent fiscal year, BDTX ran a gross margin of 99.54%, an operating margin of 28.39%, and a net margin of 31.95%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BDTX generate?
BDTX produced $29.61M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BDTX's balance sheet healthy?
BDTX holds $20.99M in cash and equivalents against — in long-term debt, on $112.21M of shareholder equity. That debt is best read against the cash flow the business throws off each year.